OncoMatch/Clinical Trials/NCT06818331
Evaluation of Clinical Efficacy and Safety of Specific Mode Electroacupuncture Stimulation for Paclitaxel Across BBB Delivery in Patients With Postoperative Recurrence of Malignant Glioma: A Single-arm Trial
Is NCT06818331 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Paclitaxel and Specific mode electroacupuncture stimulation for glioma.
Treatment: Paclitaxel · Specific mode electroacupuncture stimulation — Gliomas are the most common type of primary brain tumors, with the main treatment modalities including surgery, radiotherapy, and chemotherapy. However, gliomas are highly prone to recurrence, posing significant treatment challenges, especially for high-grade gliomas, which have a 5-year survival rate of only 5.5%. Paclitaxel (PTX) is a common chemotherapeutic agent, and its in vitro antitumor efficacy is 1400 times stronger than that of temozolomide (the first-line chemotherapy drug for gliomas). However, due to its large molecular weight (approximately 893 Da), it cannot cross the blood-brain barrier (BBB), preventing its use as a first-line treatment for gliomas. Preliminary research by our team has demonstrated that Specific Mode Electroacupuncture Stimulation (SMES) can open the BBB, increasing the concentration of PTX in tumor tissues, peritumoral tissues, and surrounding invasive tissues, thereby exerting antitumor effects. Therefore, this study aims to preliminarily observe the safety and efficacy of SMES combined with PTX in treating patients with postoperative recurrent high-grade gliomas.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Disease stage
Required: Stage IV (WHO)
Grade: IV (WHO)
WHO grade IV glioma; at least one measurable lesion per RANO 2.0
Prior therapy
Must have received: surgical resection
Recurrence confirmed by cranial MRI after surgical resection.
Cannot have received: paclitaxel or similar drugs (paclitaxel)
Those who have received treatment containing paclitaxel or similar drugs.
Lab requirements
Blood counts
Hemoglobin ≥ 90.0 g/L; White blood cells ≥ 3.0*10^9/L; Absolute neutrophil count ≥ 1500/µL; Platelets ≥ 100*10^9/µl
Kidney function
Creatinine ≤ 1.5 mg/dL, estimated glomerular filtration rate ≥ 30 mL/min to < 90 mL/min
Liver function
Total bilirubin ≤ 5.0 x ULN; SGOT ≤ 3 x ULN and TbIL ≤ 3.0 x ULN
Good bone marrow function, liver and kidney function (within 14 days before treatment): a. Hemoglobin ≥ 90.0 g/L; b. White blood cells ≥ 3.0*10^9/L; c. Absolute neutrophil count ≥ 1500/µL (white blood cell count * neutrophil percentage); d. Platelets ≥ 100*10^9/µl; e. Total bilirubin (TbIL) ≤ 5.0 x ULN; f. Serum aspartate aminotransferase (SGOT) ≤ 3 x ULN and TbIL ≤ 3.0 x ULN; g. Creatinine ≤ 1.5 mg/dL, estimated glomerular filtration rate ≥ 30 mL/min to < 90 mL/min)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify